touchNEUROLOGY met up with Prof. Giuseppe Lauria Pinter (University of Milan, Milan, Italy) to discuss the efficacy and outcome measures of a phase 2 study investigating guanabenz for the treatment of amyotrophic lateral sclerosis.
The abstract entitled: ‘The unfolded protein response in Amyotrophic lateral sclerosis: Results of a Phase 2 Trial’ was presented at the XXV Biennial World Congress of Neurology (WCN) 2021, 3 Oct 2021 – 7 Oct 2021.
- What is known about endoplasmic reticulum stress in the pathogenesis of amyotrophic lateral sclerosis (ALS)? (0:19)
- What is the mechanism of action of guanabenz? (3:46)
- What were the aims and design of your Phase II trial? (5:53)
- What were the efficacy and outcome measures and how well were they achieved? (6:42)
- What were the conclusions of the investigators and what future studies are planned? (10:53)
Disclosures: Giuseppe Lauria Pinter has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of WCN, Virtual 2021
Share this Video
Related Videos In Neuromuscular Diseases
Francesco Saccà, EAN 2022: Improving quality of life for patients with generalized myasthenia gravis – ADAPT trial findings
The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes. Questions: 1. What are the current challenges in managing cases of generalized myasthenia gravis? (00:14) […]
James Howard AAN 2022: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis – Results from the phase 3 CHAMPION-MG OLE trial
Ravulizumab has recently been approved by in the US for the treatment of adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Prof. James Howard (The University of North Carolina at Chapel Hill, NC, USA) kindly joins touchNEUROLOGY to discuss the phase 3 CHAMPION-MG trial open label extension study that evaluated the efficacy and […]
James Howard, AAN 2022: Unmet needs in the treatment of myasthenia gravis
Myasthenia gravis (MG) is a rare autoimmune disorder caused by antibodies that act against the myoneural junction, resulting in weakness of the skeletal muscles. Prof. James Howard (The University of North Carolina at Chapel Hill, CA, USA) discusses the unmet needs in the treatment of this rare disease, including, quality of life of patients, response to […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!